Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal of Oregon.
Press releases published on July 31, 2025
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and …
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today …
XORTX Announces USD $114,500 Private Placement
CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September …
Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook
WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the …
ICPO und SBMN vertiefen ihre Zusammenarbeit zur Förderung von Klinischen Theranostik-Zentren der Exzellenz in Brasilien
Die ICPO-Akkreditierung erfolgt gemäß internationalen Theranostik-Richtlinien, während die ICPO Academy for Theranostics die Partnerschaft von Anfang an stärkt. 31. Juli 2025 – Wiesbaden, Deutschland, und São Paulo, Brasilien. Auf dem Jahreskongresses der …
ICPO and SBMN deepen their collaboration to advance Clinical Theranostics Centers of Excellence in Brazil
ICPO accreditation following international theranostics guidelines and ICPO Academy for Theranostics will fuel the partnership right from start. July 31, 2025 – Wiesbaden, Germany, and Sao Paulo, Brazil. During the annual congress of the Society of Nuclear …
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC …
Integra LifeSciences Reports Second Quarter 2025 Financial Results
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 …
Do You Know the Key Differences Between Medicare and Medicaid?
Winston-Salem, NC, July 31, 2025 (GLOBE NEWSWIRE) -- Medicare and Medicaid are essential health insurance programs that help cover healthcare costs for certain American residents. Established in 1965, these two programs have similar-sounding names, which …
PL BioScience Announces Major Site Expansion
New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production Site provides the world’s largest HPL output with 20,000L annual capacity and a dual-source GMP strategy for secure, resilient supply …
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, …
Communiqué de presse : T2 : croissance à deux chiffres desventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans le haut de la fourchette à un chiffre
T2 : croissance à deux chiffres des ventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans le haut de la fourchette à un chiffre Paris, le 31 juillet 2025 Ventes du T2 en …
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth RUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second …
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional …
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology H1 core operating income of €656m, growing by 21.9% as reported, with a core operating …
Ipsen publie de solides résultats au premier semestre 2025 et relève ses objectifs financiers annuels
Croissance des ventes totales du Groupe de 11,4% à taux de change constant1 ou 9,7% en données publiées, tirée par les trois aires thérapeutiques : 95,7% dans les Maladies Rares, 9,7% en Neurosciences et 6,4% en Oncologie Résultat opérationnel des …